ABEONA THERAPEUTICS INC. (ABEO)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$61.4M
Cash & Equivalents
$19.8M
Quarterly Burn Rate
9 mo
Est. Cash Runway
$324M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT05725018 A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patien... PHASE3 Active Not Recruiting 12

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for ABEO.

SEC EDGAR Filings

All SEC filings for ABEONA THERAPEUTICS INC. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.